CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats
Roth, N.; Schoen, J.; Hoffmann, D.; Thran, M.; Thess, A.; Mueller, S. O.; Petsch, B.; Rauch, S.
Show abstract
More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by antibodies raised against ancestral SARS-CoV-2 are circulating, highlighting the need to adapt vaccination strategies. Here, we compare the immunogenicity of a first-generation mRNA vaccine candidate, CVnCoV, with a second-generation mRNA vaccine candidate, CV2CoV, in rats. Higher levels of spike (S) protein expression were observed in cell culture with CV2CoV mRNA than with CVnCoV mRNA. Vaccination with CV2CoV also induced higher titres of virus neutralising antibodies with accelerated kinetics in rats compared with CVnCoV. Significant cross-neutralization of the SARS-CoV-2 variants, Alpha (B.1.1.7), Beta (B.1.351), and the mink variant (B1.1.298) that were circulating at the time in early 2021 was also demonstrated. In addition, CV2CoV induced higher levels of antibodies at lower doses than CVnCoV, suggesting that dose-sparing could be possible with the next generation SARS-CoV-2 vaccine which could improve worldwide vaccine supply.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response 96%
- BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19 95%
- Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies 95%
Similar papers in this journal
- Non-clinical safety of GRAd vector-based COVID-19 and HIV vaccines supports a platform regulatory approach 96%
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 96%
- Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models 96%
Similar papers in this journal
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 97%
- An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose. 95%
- Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models 95%
Similar papers in this journal
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates 97%
- PF-D-Trimer, a broadly protective SARS-CoV-2 subunit vaccine: immunogenicity and application 96%
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 95%
Similar papers in this journal
- mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting 94%
- Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate 94%
- Mannose-coupled AAV2: a second generation AAV vector for increased retinal gene therapy efficiency 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.